BMS discloses expanded Erbitux use rejected, new SEC probe
This article was originally published in Scrip
Executive Summary
While Bristol-Myers Squibb had some sweet news for investors in reporting its most recent earnings, there also were a couple of bitter pills to swallow, with the firm revealing the supplemental application it submitted with its partner Lilly for Erbitux (cetuximab) to the US FDA as a first-line treatment for non-small-cell lung cancer (NSCLC) was rejected and the US Securities & Exchange Commission (SEC) has opened a new probe into the company.